• SPX
  • $5,953.83
  • 0.62 %
  • $36.72
  • DJI
  • $43,948.64
  • 1.24 %
  • $540.16
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,983.34
  • 0.09 %
  • $17.20
Nuvectis Pharma, Inc. (NVCT) Stock Price, News & Analysis

Nuvectis Pharma, Inc. (NVCT) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.93

-$0.14

(-2.76%)

Day's range
$4.69
Day's range
$5.12
50-day range
$4.685
Day's range
$11.8
  • Country: US
  • ISIN: US67080T1088
52 wk range
$4.69
Day's range
$12.1


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.73
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (NVCT)
  • Company Nuvectis Pharma, Inc.
  • Price $4.93
  • Changes Percentage (-2.76%)
  • Change -$0.14
  • Day Low $4.69
  • Day High $5.12
  • Year High $12.10

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/04/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.41
  • Trailing P/E Ratio -4.5
  • Forward P/E Ratio -4.5
  • P/E Growth -4.5
  • Net Income $-22,260,000

Income Statement

Quarterly

Annual

Latest News of NVCT

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Nuvectis Pharma, Inc. Frequently Asked Questions

  • What were the earnings of NVCT in the last quarter?

    In the last quarter Nuvectis Pharma, Inc. earnings were on Tuesday, November, 5th. The Nuvectis Pharma, Inc. maker reported -$0.24 EPS for the quarter, beating analysts' consensus estimates of -$0.26 by $0.02.

  • What is the Nuvectis Pharma, Inc. stock price today?

    Today's price of Nuvectis Pharma, Inc. is $4.93 — it has decreased by -2.76% in the past 24 hours. Watch Nuvectis Pharma, Inc. stock price performance more closely on the chart.

  • Does Nuvectis Pharma, Inc. release reports?

    Yes, you can track Nuvectis Pharma, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Nuvectis Pharma, Inc. stock forecast?

    Watch the Nuvectis Pharma, Inc. chart and read a more detailed Nuvectis Pharma, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Nuvectis Pharma, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Nuvectis Pharma, Inc. stock ticker.

  • How to buy Nuvectis Pharma, Inc. stocks?

    Like other stocks, NVCT shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Nuvectis Pharma, Inc.'s EBITDA?

    Nuvectis Pharma, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Nuvectis Pharma, Inc.’s financial statements.

  • What is the Nuvectis Pharma, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Nuvectis Pharma, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Nuvectis Pharma, Inc.'s financials relevant news, and technical analysis. Nuvectis Pharma, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Nuvectis Pharma, Inc. stock currently indicates a “sell” signal. For more insights, review Nuvectis Pharma, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.